Related references
Note: Only part of the references are listed.Antisense Approach to Inflammatory Bowel Disease: Prospects and Challenges
Irene Marafini et al.
DRUGS (2015)
Review article: anti-adhesion therapies for inflammatory bowel disease
T. Lobaton et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis
S. Vegter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD
Jessica R. Philpott et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos
Paul A. Morcos
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease
Bruce Yacyshyn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis
SJH Van Deventer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial
PB Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis
PB Miner
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis
P Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis
SJH van Deventer et al.
GUT (2004)
Progress in antisense technology
ST Crooke
ANNUAL REVIEW OF MEDICINE (2004)
Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease
BR Yacyshyn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
BR Yacyshyn et al.
GUT (2002)
Subcellular localization of intercellular adhesion molecule-1 in colonic mucosa in ulcerative colitis
B Vainer et al.
ULTRASTRUCTURAL PATHOLOGY (2002)
Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice
RC Burns et al.
GASTROENTEROLOGY (2001)
Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2001)
Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease
B Vainer et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2000)
Share Paper
